← Leaderboards
Towia A Libermann
Beth Israel Deaconess Medical Center
$13,917,325
Attributed
$17,546,694
Total exposure
18
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,546,694 · 18
By mechanism
R01$10,961,024 · 6
P30$2,244,803 · 3
U24$1,626,809 · 1
R21$1,484,194 · 4
P01$1,229,864 · 4
Top collaborators
- Edward R Marcantonio9 shared
- Balachundhar Subramaniam1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Joel K Elmquist$39,930,443
- Robert C Flaumenhaft$19,499,862
- Edward R Marcantonio$19,902,198
- Balachundhar Subramaniam$4,759,796
- Raghu Kalluri$29,360,132
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsBloodProteomicsSamplingSystems BiologyValidationInsightDiagnosisBiomarker DiscoveryTechnologyMalignant NeoplasmsCerebrospinal FluidMetabolomicsGenerationsEnzyme-Linked Immunosorbent AssayClinical TrialsServicesSignal PathwayBioinformaticsBaseData AnalysesOutcome ForecastConsultationsDrug Development
Grant awards (63)
Proteomic Signatures of Delirium and Longterm Cognitive Decline in Older Cardiac Surgical Patients$1,631,690
R01 · FY2025 · AG
AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline$831,700
R01 · FY2025 · AG
AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline$870,666
R01 · FY2024 · AG
AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline$874,146
R01 · FY2023 · AG
Cancer Proteomics Core$1
P30 · FY2023 · CA · contact PI
Cancer Proteomics Core$1
P30 · FY2022 · CA · contact PI
Shared Resource 04 Cancer Proteomics$176,049
P30 · FY2021 · CA · contact PI
Shared Resource 04 Cancer Proteomics$175,936
P30 · FY2020 · CA · contact PI
Shared Resource 04 Cancer Proteomics$2,949
P30 · FY2020 · CA · contact PI
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics$485,512
R01 · FY2019 · AG
Identification of Plasma- and Exosome-Based Protein Biomarkers for Early Detection of Pancreatic Cancer Using SOMAscan Technology$184,603
R21 · FY2019 · CA · contact PI
Shared Resource 04 Cancer Proteomics$174,305
P30 · FY2019 · CA · contact PI
Shared Resource 04 Cancer Proteomics$6,169
P30 · FY2019 · CA · contact PI
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics$622,313
R01 · FY2018 · AG
Identification of Plasma- and Exosome-Based Protein Biomarkers for Early Detection of Pancreatic Cancer Using SOMAscan Technology$228,375
R21 · FY2018 · CA · contact PI
Shared Resource 04 Cancer Proteomics$175,965
P30 · FY2018 · CA · contact PI
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics$166,112
R01 · FY2018 · AG
Shared Resource 04 Cancer Proteomics$11,431
P30 · FY2018 · CA · contact PI
Shared Resource 04 Cancer Proteomics$5,849
P30 · FY2018 · CA · contact PI
Shared Resource 04 Cancer Proteomics$5,124
P30 · FY2018 · CA · contact PI
Shared Resource 04 Cancer Proteomics$3,835
P30 · FY2018 · CA · contact PI
Shared Resource 04 Cancer Proteomics$1,603
P30 · FY2018 · CA · contact PI
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics$602,453
R01 · FY2017 · AG
Shared Resource 04 Cancer Proteomics$156,413
P30 · FY2017 · CA · contact PI
Advancing the Understanding of Postoperative Delirium Mechanisms via Multi-Omics$630,249
R01 · FY2016 · AG
Cancer Proteomics$276,508
P30 · FY2016 · CA · contact PI
Role of Axl in docetaxel resistance in prostate cancer$160,515
R21 · FY2016 · CA · contact PI
Cancer Proteomics$276,797
P30 · FY2015 · CA · contact PI
Role of Axl in docetaxel resistance in prostate cancer$211,118
R21 · FY2015 · CA · contact PI
Cancer Proteomics$263,930
P30 · FY2014 · CA · contact PI
Novel treatment strategies for enhancing sunitinib response in renal cell cancer$183,549
R21 · FY2014 · CA · contact PI
Cancer Proteomics$255,155
P30 · FY2013 · CA · contact PI
Novel treatment strategies for enhancing sunitinib response in renal cell cancer$227,070
R21 · FY2013 · CA · contact PI
Cancer Proteomics$276,783
P30 · FY2012 · CA · contact PI
CORE--GENOMIC AND BIOINFORMATICS SUPPORT$110,375
P01 · FY2008 · HL · contact PI
CORE--GENOMIC AND BIOINFORMATICS SUPPORT$127,141
P01 · FY2007 · HL · contact PI
NOVEL APPROACHES TO GENE PROFILING IN OVARIAN CANCER$142,764
R21 · FY2006 · CA · contact PI
CORE-- GENOMIC AND BIONFORMATICS SUPPORT$124,928
P01 · FY2006 · HL · contact PI
Ese-1, a New Transcriptional Mediator of Inflammation$340,000
R01 · FY2005 · AI
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER$251,388
R01 · FY2005 · CA
NOVEL APPROACHES TO GENE PROFILING IN OVARIAN CANCER$146,200
R21 · FY2005 · CA
CORE-- GENOMIC AND BIONFORMATICS SUPPORT$121,290
P01 · FY2005 · HL
Ese-1, a New Transcriptional Mediator of Inflammation$340,000
R01 · FY2004 · AI
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER$251,388
R01 · FY2004 · CA
CORE-- GENOMIC AND BIONFORMATICS SUPPORT$117,757
P01 · FY2004 · HL
Ese-1, a New Transcriptional Mediator of Inflammation$340,000
R01 · FY2003 · AI
NEW ETS FACTOR, ESE-1, AND EPITHELIAL CELLS$272,848
R01 · FY2003 · CA
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER$251,388
R01 · FY2003 · CA
NIDDK BIOTECHNOLOGY CENTER$595,856
U24 · FY2002 · DK
Ese-1, a New Transcriptional Mediator of Inflammation$365,000
R01 · FY2002 · AI
NEW ETS FACTOR, ESE-1, AND EPITHELIAL CELLS$264,898
R01 · FY2002 · CA
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER$251,388
R01 · FY2002 · CA
Core--Genomics/Microarray$0
P01 · FY2002 · AI
Core--Angiogenesis Genomics and Bioinformatics Core$0
P01 · FY2002 · CA
NIDDK BIOTECHNOLOGY CENTER$596,124
U24 · FY2001 · DK
Ese-1, a New Transcriptional Mediator of Inflammation$323,000
R01 · FY2001 · AI
ROLE OF A NEW ETS FACTOR, PDEF, IN PROSTATE CANCER$287,300
R01 · FY2001 · CA
FUNCTIONS OF ELF-1 AND A NOVEL ETS FACTOR NERF IN B CELLS$279,549
P01 · FY2001 · CA
NEW ETS FACTOR, ESE-1, AND EPITHELIAL CELLS$257,182
R01 · FY2001 · CA
NIDDK BIOTECHNOLOGY CENTER$434,829
U24 · FY2000 · DK
FUNCTIONS OF ELF-1 AND A NOVEL ETS FACTOR NERF IN B CELLS$348,824
P01 · FY2000 · CA
NEW ETS FACTOR, ESE-1, AND EPITHELIAL CELLS$249,692
R01 · FY2000 · CA
GENE TRANSFER APPROACH TO PREVENT TRANSPLANT REJECTION$200,711
R01 · FY2000 · DK